Comprehensive Stock Comparison
Compare Kiniksa Pharmaceuticals, Ltd. (KNSA) vs Akari Therapeutics, Plc (AKTX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | KNSA | Beta 0.46 vs AKTX's 0.63, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | KNSA | +119.4% vs AKTX's -72.9% |
| Efficiency (ROA) | KNSA | 15.5% ROA vs AKTX's -34.7%, ROIC 17.1% vs -172.5% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Kiniksa Pharmaceuticals is a biopharmaceutical company that develops and commercializes treatments for inflammatory and autoimmune diseases. It generates revenue primarily from sales of ARCALYST for recurrent pericarditis — its only approved product — with additional income from licensing and collaboration agreements. The company's competitive advantage lies in its targeted pipeline of monoclonal antibodies addressing specific immune pathways with high unmet medical needs.
Akari Therapeutics is a clinical-stage biopharmaceutical company developing advanced therapies for autoimmune and inflammatory diseases. It generates no revenue currently — its business model depends on advancing its lead candidate nomacopan through clinical trials to eventually secure regulatory approvals and commercialization partnerships. The company's key advantage lies in nomacopan's dual mechanism of action targeting both complement and leukotriene pathways — a differentiated approach that could offer superior efficacy in treating complex inflammatory conditions.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
KNSA leads in 4 of 6 categories (Financial Metrics, Profitability & Efficiency). AKTX leads in 1 (Valuation Metrics).
Financial Metrics (TTM)
KNSA and AKTX operate at a comparable scale, with $678M and $0 in trailing revenue.
| Metric | KNSAKiniksa Pharmaceu… | AKTXAkari Therapeutic… |
|---|---|---|
| RevenueTrailing 12 months | $678M | $0 |
| EBITDAEarnings before interest/tax | $79M | -$17M |
| Net IncomeAfter-tax profit | $119M | -$16M |
| Free Cash FlowCash after capex | $136M | -$10M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | +11.4% | — |
| Net MarginNet income ÷ Revenue | +17.5% | — |
| FCF MarginFCF ÷ Revenue | +20.1% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +65.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +2.5% | -80.2% |
Valuation Metrics
| Metric | KNSAKiniksa Pharmaceu… | AKTXAkari Therapeutic… |
|---|---|---|
| Market CapShares × price | $3.4B | $12.6B |
| Enterprise ValueMkt cap + debt − cash | $3.2B | $12.6B |
| Trailing P/EPrice ÷ TTM EPS | 59.32x | -0.00x |
| Forward P/EPrice ÷ next-FY EPS est. | 34.78x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 41.03x | — |
| Price / SalesMarket cap ÷ Revenue | 5.01x | — |
| Price / BookPrice ÷ Book value/share | 6.19x | 0.00x |
| Price / FCFMarket cap ÷ FCF | 133.57x | — |
Profitability & Efficiency
KNSA delivers a 20.9% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-69 for AKTX. KNSA carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to AKTX's 0.15x. On the Piotroski fundamental quality scale (0–9), KNSA scores 6/9 vs AKTX's 3/9, reflecting solid financial health.
| Metric | KNSAKiniksa Pharmaceu… | AKTXAkari Therapeutic… |
|---|---|---|
| ROE (TTM)Return on equity | +20.9% | -69.4% |
| ROA (TTM)Return on assets | +15.5% | -34.7% |
| ROICReturn on invested capital | +17.1% | -172.5% |
| ROCEReturn on capital employed | +14.0% | -142.3% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 3 |
| Debt / EquityFinancial leverage | 0.02x | 0.15x |
| Net DebtTotal debt minus cash | -$156M | $661,000 |
| Cash & Equiv.Liquid assets | $166M | $3M |
| Total DebtShort + long-term debt | $9M | $3M |
| Interest CoverageEBIT ÷ Interest expense | — | -47.14x |
Total Returns (with DRIP)
A $10,000 investment in KNSA five years ago would be worth $20,324 today (with dividends reinvested), compared to $35 for AKTX. Over the past 12 months, KNSA leads with a +119.4% total return vs AKTX's -72.9%. The 3-year compound annual growth rate (CAGR) favors KNSA at 51.2% vs AKTX's -67.5% — a key indicator of consistent wealth creation.
| Metric | KNSAKiniksa Pharmaceu… | AKTXAkari Therapeutic… |
|---|---|---|
| YTD ReturnYear-to-date | +5.9% | -18.6% |
| 1-Year ReturnPast 12 months | +119.4% | -72.9% |
| 3-Year ReturnCumulative with dividends | +246.0% | -96.6% |
| 5-Year ReturnCumulative with dividends | +103.2% | -99.6% |
| 10-Year ReturnCumulative with dividends | +128.5% | -99.9% |
| CAGR (3Y)Annualised 3-year return | +51.2% | -67.5% |
Risk & Volatility
KNSA is the less volatile stock with a 0.46 beta — it tends to amplify market swings less than AKTX's 0.63 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KNSA currently trades 90.6% from its 52-week high vs AKTX's 13.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KNSAKiniksa Pharmaceu… | AKTXAkari Therapeutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.46x | 0.63x |
| 52-Week HighHighest price in past year | $49.12 | $1.73 |
| 52-Week LowLowest price in past year | $18.26 | $0.22 |
| % of 52W HighCurrent price vs 52-week peak | +90.6% | +13.7% |
| RSI (14)Momentum oscillator 0–100 | 47.3 | 52.2 |
| Avg Volume (50D)Average daily shares traded | 469K | 387K |
Analyst Outlook
Wall Street rates KNSA as "Buy" and AKTX as "Buy". Consensus price targets imply 12601.1% upside for AKTX (target: $30) vs 25.1% for KNSA (target: $56).
| Metric | KNSAKiniksa Pharmaceu… | AKTXAkari Therapeutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $55.67 | $30.00 |
| # AnalystsCovering analysts | 10 | 7 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.2% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Kiniksa Pharmaceuti… (KNSA) | 100 | 236.47 | +136.5% |
| Akari Therapeutics,… (AKTX) | 100 | 0.63 | -99.4% |
Kiniksa Pharmaceuti… (KNSA) returned +103% over 5 years vs Akari Therapeutics,… (AKTX)'s -100%. A $10,000 investment in KNSA 5 years ago would be worth $20,324 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Kiniksa Pharmaceuti… (KNSA) | $0.00 | $678M | — |
| Akari Therapeutics,… (AKTX) | $0.00 | $0.00 | — |
Kiniksa Pharmaceuticals, Ltd.'s revenue grew from $0M (2016) to $678M (2025) — a 0.0% CAGR.
Chart 3P/E Ratio History — 3 Years
| Stock | 2022 | 2025 | Change |
|---|---|---|---|
| Kiniksa Pharmaceuti… (KNSA) | 5.8 | 55 | +848.3% |
Kiniksa Pharmaceuticals, Ltd. has traded in a 6x–88x P/E range over 3 years; current trailing P/E is ~59x.
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Kiniksa Pharmaceuti… (KNSA) | -0.74 | 0.75 | +201.4% |
| Akari Therapeutics,… (AKTX) | -3,080 | -1,660 | +46.1% |
Kiniksa Pharmaceuticals, Ltd.'s EPS grew from $-0.74 (2016) to $0.75 (2025).
Chart 5Free Cash Flow — 5 Years
Kiniksa Pharmaceuticals, Ltd. generated $25M FCF in 2025 (+117% vs 2021). Akari Therapeutics, Plc generated $-13M FCF in 2024 (+33% vs 2021).
KNSA vs AKTX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is KNSA or AKTX a better buy right now?
Kiniksa Pharmaceuticals, Ltd. (KNSA) offers the better valuation at 59.3x trailing P/E (34.8x forward), making it the more compelling value choice. Analysts rate Kiniksa Pharmaceuticals, Ltd. (KNSA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KNSA or AKTX?
Over the past 5 years, Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered a total return of +103.2%, compared to -99.6% for Akari Therapeutics, Plc (AKTX). A $10,000 investment in KNSA five years ago would be worth approximately $20K today (assuming dividends reinvested). Over 10 years, the gap is even starker: KNSA returned +128.5% versus AKTX's -99.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KNSA or AKTX?
By beta (market sensitivity over 5 years), Kiniksa Pharmaceuticals, Ltd. (KNSA) is the lower-risk stock at 0.46β versus Akari Therapeutics, Plc's 0.63β — meaning AKTX is approximately 36% more volatile than KNSA relative to the S&P 500. On balance sheet safety, Kiniksa Pharmaceuticals, Ltd. (KNSA) carries a lower debt/equity ratio of 2% versus 15% for Akari Therapeutics, Plc — giving it more financial flexibility in a downturn.
04Which has better profit margins — KNSA or AKTX?
Kiniksa Pharmaceuticals, Ltd. (KNSA) is the more profitable company, earning 17.5% net margin versus 0.0% for Akari Therapeutics, Plc — meaning it keeps 17.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KNSA leads at 11.4% versus 0.0% for AKTX. At the gross margin level — before operating expenses — KNSA leads at 0.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is KNSA or AKTX more undervalued right now?
Analyst consensus price targets imply the most upside for AKTX: 12601.1% to $30.00.
06Which pays a better dividend — KNSA or AKTX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is KNSA or AKTX better for a retirement portfolio?
For long-horizon retirement investors, Kiniksa Pharmaceuticals, Ltd. (KNSA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.46), +128.5% 10Y return). Both have compounded well over 10 years (KNSA: +128.5%, AKTX: -99.9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between KNSA and AKTX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.